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Abstract
Background: Equine herpesvirus type 1 (EHV-1), a member of the Alphaherpesvirinae, is spread via nasal secretions and
causes respiratory disease, neurological disorders and abortions. The virus is a significant equine pathogen, but current EHV-
1 vaccines are only partially protective and effective metaphylactic and therapeutic agents are not available. Small
interfering RNAs (siRNA’s), delivered intranasally, could prove a valuable alternative for infection control. siRNA’s against two
essential EHV-1 genes, encoding the viral helicase (Ori) and glycoprotein B, were evaluated for their potential to decrease
EHV-1 infection in a mouse model.
Methodology/Principal Fndings: siRNA therapy in vitro significantly reduced virus production and plaque size. Viral titers
were reduced 80-fold with 37.5 pmol of a single siRNA or with as little as 6.25 pmol of each siRNA when used in
combination. siRNA therapy in vivo significantly reduced viral replication and clinical signs. Intranasal treatment did not
require a transport vehicle and proved effective when given up to 12 h before or after infection.
Conclusions/Significance: siRNA treatment has potential for both prevention and early treatment of EHV-1 infections.
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Introduction
Equine herpesvirus type 1 (EHV-1) is a major cause of
respiratory, neurologic and reproductive disease in horses
worldwide. EHV-1 is a member of the Alphaherpesvirinae and
closely related to the causative agents of human chicken pox/
shingles (varicella zoster virus, VZV) as well as cold sores and
genital herpes, herpes simplex types 1 (HSV-1) and 2 (HSV-2) [1].
EHV-1 is spread through respiratory secretions and replicates in
the nasal epithelium upon gaining access to the respiratory tract.
Initial replication is followed by a leukocyte-associated viremia.
Further replication of EHV-1 can occur in endothelia of blood
vessels of the central nervous system (CNS) and the uterus, where
vasculitis can lead to myeloencephalopathy or abortion, respec-
tively [2]. EHV-1 establishes latency in neural and lymphoid tissue
and recrudesces in times of stress such as transportation,
pregnancy, competitions, and racing [3]. Therefore, horses
traveling to competitions and coming into contact with new
animals are at risk of shedding or contracting the virus, making
this viral infection a huge concern for the performance horse
industry. Recently, an increased occurrence of neurologic EHV-1
outbreaks, especially of the neurologic form of the disease, has
been reported, and these outbreaks are more and more frequently
associated with high mortality rates. Consequently, EHV-1 has
recently been classified as a potentially emerging disease by the US
Department of Agriculture [4].
Unfortunately, vaccination is currently the only form of EHV-1
control and the available vaccines do not provide complete
protection. As EHV-1-induced protective immunity is only short-
lived, vaccination has to be repeated at least every 6 months [5].
However, the continuing EHV-1 outbreaks involving large numbers
of animals raises the question as to whether repeated vaccination by
itself is sufficient to protect animals in outbreak situations. Moreover,
repeated vaccination has recently been suggested to predispose horses
to develop the most severe form of EHV-1 infection, myeloencepha-
lopathy [5–7]. Treatment of EHV-1 infections is reduced to
symptomatic care and experimental antiviral drugs have yet to prove
clinical efficacy. For example, drugs such as acyclovir or valacyclovir
were shown to have serious limitations due to poor bioavailability and
high therapeutic concentrations are needed in order to reach the
desired effect, making these drugs a costly medication with
questionable efficacy [8–10].
RNA interference mediated by small interfering RNA’s
(siRNA’s) is an important defense mechanism against viral
infections in plants. siRNA’s have recently been intensively
examined for their ability to prevent and/or treat viral infections.
siRNA’s bind to complementary target mRNA and, upon
interaction with the cellular RNA interference mechanisms, will
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specifically target these sequences for degradation, resulting in
inhibition of protein expression [11,12]. Synthetic siRNA’s have
been shown to successfully inhibit viral replication of several
viruses, among them herpesviruses [13–15]. In addition, siRNA’s
against respiratory viruses have been tested extensively in animal
models. It has been demonstrated that siRNA’s effectively
inhibited the replication of SARS coronavirus in rhesus macaques
[16]. Additionally, intranasally administered siRNA’s targeting
viral genes of parainfluenza virus and respiratory syncytial virus
were shown to be effective in preventing pulmonary disease and
pathology in mice [17].
In the present study, we evaluated the use of siRNA therapy to
limit and prevent EHV-1 infection in vitro and in a murine model
of EHV-1 infection. Synthetic siRNA’s were designed against two
essential and highly conserved EHV-1 genes. Firstly, the open
reading frame (ORF) 33 encoding the envelope glycoprotein B
(gB) was chosen because this glycoprotein is essential for viral entry
and cell-to-cell spread [18]. Secondly, siRNA’s against ORF53,
encoding the origin-binding protein (Ori) helicase, were designed
as this protein is essential for the initiation of herpesviral genome
replication [19,20].
Results
Treatment with siRNA targeting glycoprotein B or the
origin-binding protein helicase is effective in reducing
EHV-1 replication in vitro
EHV-1 glycoprotein B (gB), an envelope protein essential for
viral entry into cells and cell-to-cell spread [18], and origin-
binding protein (Ori) helicase, an enzyme necessary for EHV-1
genome replication [19], were chosen as possible targets for RNA
interference. siRNA’s against these proteins were synthesized and
evaluated for their effectiveness to reduce EHV-1 replication.
sigB3, directed against gB mRNA, efficiently reduced viral
replication in a dose-dependent manner. A 10-fold reduction of
viral titers was observed with as low as 6.25 pmol sigB3 (p,0.05)
and reached a steady-state level starting at 37.5 pmol with up to a
100-fold reduction in viral titers (p,0.01) (Figure 1A). Treating
cells with siOri2, directed against the Ori helicase mRNA, resulted
in a 50-fold reduction in viral titers, at a concentration ranging
between 37.5 and 75 pmol (p,0.05). Furthermore, these siRNA’s
were also able to significantly reduce plaque sizes, with up to a
60% reduction in total plaque area when 37.5 pmol sigB3 or
75pmol siOri2 was used (p,0.05) (Figure 1B).
To evaluate siRNA transfection efficiency, cells were transfected
with commercially available siGFP, an siRNA targeting the egfp
gene. eGFP-expressing EHV-1 strain rAb4Dgp2 was used for in
vitro studies because eGFP expression allows for ready identifica-
tion of infected cells and virus-induced plaques. Pre-treating cells
with 75 pmol siGFP efficiently reduced eGFP expression in
infected cells (Figure 1C), without having any effect on EHV-1
infectivity, i.e. plaque sizes and titers remained unaffected even
though eGFP expression was no longer detectable (Figure 1C). To
ensure that siRNA transfection by itself did not have a negative
effect on EHV-1 infectivity, cells were treated with 75 pmol of the
negative control siRNA siLuc, an siRNA targeting the luciferase
gene, before infection. As expected, because the rAb4Dgp2 does
not express luciferase, we did not observe any effect on eGFP
expression (Figure 1C) or on viral infectivity when compared to
mock-treated cells (Figure 1C).
To assess the effectiveness of sigB3 and siOri2 at the mRNA
level, relative quantitation of the two mRNA’s was performed
using quantitative reverse transcriptase PCR (qRT-PCR). At 12 h
p.i., the relative quantity of gB or Ori mRNA was reduced by
more than 90% following sigB3 or Ori2 treatment, respectively,
when compared to untreated cells (p,0.05) (Figure 2A). No
significant difference in gB or Ori mRNA levels in cells was
observed between (i) untreated cells and cells treated with the
control siRNA siLuc (Figure 2A), and (ii) the control siRNA’s
siGFP and siLuc (data not shown). The effectiveness of silencing
gB was also evaluated at the protein level by western blot analysis.
Using the anti-gB antibody 3F6, a clear reduction in protein
expression was observed in cells treated with sigB3 compared to
non-treated cells or cells treated with control siLuc siRNA
(Figure 2B). Mock-infected cells did not express gB and the
control antibody against b-actin showed that equal amounts of cell
proteins were loaded in each lane (Figure 2B).
We concluded from the data that siRNA treatment targeting
EHV-1 gB or Ori can significantly reduce EHV-1 infection by
effectively silencing gB or Ori expression at the mRNA and
protein level. The silencing of these two essential EHV-1 proteins
resulted in significantly reduced viral titers and plaque sizes.
Treatment with siRNA targeting two essential EHV-1
genes has an additive effect on reduction of EHV-1
replication in vitro
In the next series of experiments we repeated treatment but
used combinations of the two siRNA’s. When applied together,
gB3 and siOri2 showed the same effectiveness in reducing EHV-1
infectivity, but at a much lower concentration than either siRNA
by itself. As seen in Figure 3A, the 80-fold reduction in viral titers
observed after treatment with either 37.5 pmol sigB3 or 50 pmol
siOri2 was also obtained when using a combination of 6.25 pmol
sigB3 and 6.25 pmol siOri2 (p,0.05). Surprisingly, a combination
of higher concentrations of sigB3 and siOri2 (e.g. 37.5 pmol each
or 12.5 pmol each) was less effective in reducing viral titers than
the lower concentration of 6.25 pmol each (Figure 3A). Such an
observation has also been reported for siRNA combinations
against human respiratory viruses, where the inhibitory activity of
one siRNA was inhibited when using high amounts of another
siRNA at the same time [17]. It is known that cells have a limited
capacity to assemble the RNA-induced silencing complex (RISC)
onto transfected siRNA and that siRNA’s differ in their specificity
and efficiency of RISC targeting [21]. A possible explanation
could therefore be that both siRNA’s compete for the available
RISC pool present in the cell and as such inhibit each other at
higher concentrations. The effectiveness of this 6.25 pmol
combination cocktail on gB silencing was also evaluated with
both qRT-PCR and Western blot analysis and resulted in similar
observations as described before with 37.5 pmol sigB3 (data not
shown). These data indicate that targeting multiple genes
simultaneously is as effective in reducing viral replication as when
one gene is targeted, and does so with significantly lower
concentrations of each of the individual siRNA’s.
sigB3 and siOri2, alone or in combination, also inhibit
viral replication after infection
Finally, the last set of in vitro experiments evaluated the efficacy
of siRNA addition in function of time. Cells were transfected with
siRNA’s at different time points before (12, 6 and 2 h),
simultaneously, and 1 h after infection. It was observed that sigB3
(37.5 pmol) could significantly reduce viral replication when
applied at any time between 12 h prior to and up to 1 h after
infection (p,0.05) (Figure 3B). siOri2 at a concentration of
75 pmol reduced viral titers significantly when transfection and
infection occurred simultaneously or when siOri2 was transfected
EHV-1 Treatment Using siRNA
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1 h after infection (p,0.05) (Figure 3B). The combination of sigB3
and siOri2 at 6.25 pmol each, significantly decreased viral titers at
all time points tested (p,0.05), with the exception of 12 h before
infection (Figure 3B). There was no significant difference at all
time points tested between the control treatments that included
cells treated with siGFP, siLuc or no siRNA (data not shown).
Taken together, the in vitro experiments clearly showed that siRNA
treatment is not only effective in reducing EHV-1 replication when
used before infection, but is as efficient, if not even more, when
applied during or after the onset of EHV-1 replication.
Intranasal administration of siRNA reduces clinical sings
and viral replication in a murine model of EHV-1 infection
The efficiency of siRNA therapy in vitro clearly showed that
cellular replication and spread of EHV-1 can be prevented in cell
Figure 1. Effect of siRNA’s targeting glycoprotein B (gB) and origin-binding protein (ori) helicase on EHV-1 replication and cell-to-
cell spread. (A). siRNA’s targeting gB (sigB3) or Ori (siOri2) were transfected into RK13 cells and cells were infected with 100 PFU of EHV-1 strain
rAb4Dgp2 14 h later. Supernatants were collected 24 h p.i. from sigB3- (%) and siOri2-transfected cells (e), and viral titers were determined with
standard plaque assays. Asterisks indicate statistically significant differences (*: p,0.05, **: p,0.01). (B). Cells were fixed with 10% formalin and the
average plaque areas were determined. Asterisks indicate statistically significant differences (p,0.05). (C). As controls cells were included, which were
either not transfected with siRNA or were transfected with 75 pmol siGFP or siLuc before infection with rAb4Dgp2. Representative pictures were
taken with light and fluorescent microscopy (a) and viral titers were determined with standard plaque assays (b).
doi:10.1371/journal.pone.0004118.g001
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culture. A murine model was used to assess whether siRNA
treatment is also effective in vivo. This mouse model of EHV-1
infection, first described by Awan et al. in 1990 [22], has been
intensively used to predict the efficacy of putative EHV-1 vaccines
in horses [23–26], as well as the virulence potential of several
EHV-1 strains [27–32]. In the present study, mice were
anaesthetized and inoculated intranasally with siRNA’s, followed
by infection with 16105 PFU Ab4 by the same route. The
amounts and combinations of siRNA’s used, as well as the time
points of siRNA treatment and EHV-1 infection are summarized
in Table 1.
In an initial experimental set up, siRNA treatment with sigB3
and siOri2, given alone or in combination at 24 h and 0.5 h
before infection with EHV-1, was evaluated. Mice (12 per group)
treated with the control siRNA siLuc began losing weight as early
as 1 day p.i. and continued to lose weight until day 3 p.i., when a
maximum weight loss of up to 17% of their original body weights
was observed. Pre-infection weights were regained only at day 12
p.i. (Figure 4A). These results were comparable to those obtained
from mice that only received the siRNA transfection reagent
lipofectamine before infection (data not shown). Mice treated with
siRNA’s targeting EHV-1 genes 0.5 h before infection also lost
weight during the first 2 days p.i., but this weight loss only reached
a maximum of 10% for the mice treated with 187.5 pmol siOri2
and the combination sigB3/siOri2 (31.25 pmol and 62.5 pmol,
respectively). Mice treated with 187.5 pmol siOri2 and 62.5 pmol
sigB3/siOri2 regained their original body weight by day 8 p.i., and
mice treated with 31.25 pmol sigB3/siOri2 by day 10 p.i.
(Figure 4A). The group treated with 187.5 pmol sigB3 lost up to
15% of their body weight and took until day 14 p.i. to regain their
pre-infection weights. However, mice started regaining weight
already by day 3 p.i., which is in contrast to the control siLuc
treated group where the mice didn’t start regaining weight until
day 8 p.i. The differences between sigB3/siOri2-treated mice and
those treated with control siRNA’s or transfection reagents alone
were statistically significant on days 3–9 p.i. (non-parametric
statistical testing, p,0.05) (Figure 4A). The uninfected control
Figure 2. siRNA’s efficiently suppresses gB and Ori expression
at the mRNA and protein level. (A). Relative qRT-PCR. RK13 cells
were transfected with 37.5 pmol sigB3, 75 pmol siOri2, 75 pmol siLuc or
not transfected. Cells were infected 14 h later with 500 PFU of
rAb4Dgp2 and at 12 h p.i., RNA was extracted from infected cells. RT-
PCR was used to determine relative levels of gB or Ori (white bars) or
EHV-1 IR6 (grey bars) mRNA, using rabbit b-actin as the endogenous
housekeeping gene. Asterisks indicate statistically significant differenc-
es (p,0.05). (B). Western blot analysis. RK13 cells were either not
transfected or transfected with 75 pmol of the control siRNA siLuc or
75 pmol sigB3. Cells were infected 14 h later with 500 PFU of
rAb4Dgp2. At 24 h p.i., cell lysates were prepared and analyzed by
SDS-PAGE under reducing conditions. Anti-gB mAb 3F6 (1/500) and
anti-b-actin (1/5000), followed by anti-mouse IgG peroxidase (1/7500)
were used. Cell lysates from non-infected RK13 cells were included as a
control.
doi:10.1371/journal.pone.0004118.g002
Figure 3. Combining siRNA’s have an additive effect on
reduction of EHV-1 replication and are effective before and
after infection. (A). The siRNA’s sigB3 and siOri2 were transfected into
RK13 cells, either alone or in different combinations, and cells were
infected 14 h later with 500 PFU of rAb4Dgp2. Supernatants were
collected 24 h p.i. and viral titers were determined with standard
plaque assays. Asterisks indicate statistically significant differences
(p,0.05). (B). RK13 cells were transfected with 75 pmol control siRNA
(black bars), 37.5 pmol sigB3 (grey bars), 75 pmol siOri2 (hatched bars)
or a combination of 6.25 pmol sigB3 and 6.25 pmol siOri2 (white bars).
At different times after transfection (ranging form 12 h up to 0 h) cells
were infected with 500 PFU of rAb4Dgp2 and supernatants were
collected at 24 h p.i. In one set of experiments, cells were first infected
with rAb4Dgp2 and transfected with the different siRNA’s 1 h later. Viral
titers were determined with standard plaque assays. Asterisks indicate
statistically significant differences (p,0.05).
doi:10.1371/journal.pone.0004118.g003
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group did not show any weight loss, indicating that the repeated
anesthesia protocols used for the intranasal application of siRNA’s
and virus did not have any effect on weight loss (Figure 4A). Since
body weight loss caused by EHV-1 infection is strongly associated
with an inflammatory response in lungs of infected mice, we
validated the data on weight loss by histopathological analyses of
lung tissues obtained on days 2 and 4 p.i. The lungs of mice
treated with control siLuc had the most pronounced hyperplasia of
bronchiolar epithelium at day 2 p.i., the most necrotic cells in the
airway lumina, the most inclusion bodies as well as the most
significant interstitial inflammation (Figure 4B&C). Lungs of mice
treated with sigB3 were slightly less affected and lungs of mice
treated with siOri2 or the sigB3/Ori2 combinations were clearly
less affected compared to the siLuc control group (Figure 4B&C).
With regard to virus titers, mice inoculated with control siLuc
had titers around 36103 PFU/mg lung tissue on day 2 p.i.
(Figure 5A). In contrast, virus titers in lungs of mice treated 0.5 h
before infection with sigB3 and siOri2, either alone or in various
combinations, showed a significant reduction in viral titers with an
average of 36102 PFU/mg lung tissue (Student’s t-test, p,0.05)
(Figure 5A). A similar reduction in virus titers was observed on day
4 p.i., although declining virus titers at that day generally indicates
beginning clearance of the virus infection (data not shown).
Treatment with siRNA’s targeting EHV-1 genes at 24 h before
infection also showed a reduction in body weight loss and virus
titers to some extent when compared to the control siRNA group,
albeit without reaching statistical significance. All infected mice
showed maximal weight loss at day 4 p.i., with around 20% in the
group of mice that received the control siLuc and only 15–17% in
mice treated with siRNA’s against EHV-1 genes. In addition,
original body weights were regained 1 or 2 days earlier in the
treated groups, compared to mice treated with control siLuc, in
which pre-infection weights were only reached as late as 13 days
p.i. Titers of 1.767.76103 PFU/mg lung tissue were observed in
the siLuc-treated group, which were slightly higher than in lungs
of mice treated with sigB3 (4.464.26102 PFU/mg), siOri2
(1.466.56103 PFU/mg) or the sigB3/siOri2 combinations
(1.661.36102 PFU/mg and 1.361.06103 PFU/mg for
31.25 pmol sigB3/siOri2 and 62.5 pmol sigB3/siOri2 respective-
ly). Taken together, this first in vivo experiment clearly revealed
that siRNA therapy is effective in vivo by reducing clinical
symptoms in challenge-infected animals and was capable of
significantly reducing inflammation and viral replication in the
target organ, the lung, at least when applied 0.5 h before infection.
Since it has been described previously that siRNA application to
mucosal surfaces in vivo does not require a transfection vehicle [17],
a second experiment in mice was performed without a transfection
agent. In addition, to extrapolate our previous findings to other
time points, we included siRNA treatments 12 h and 6 h before
infection with EHV-1. The siRNA combination of 62.5 pmol
sigB3/siOri2 was evaluated, since this treatment group was shown
to significantly reduce both weight loss and virus replication. First,
it was observed that intranasal application of sigB3/siOri2 did not
require a transfection reagent because no significant differences in
weight loss (data not shown) and viral titers (Student’s t-test,
p,0.05) (Figure 5B) were observed when siRNA’s were delivered
with either lipofectamine or PBS. Secondly, it was observed that
siRNA treatment 12 h before infection was effective in signifi-
Table 1. Protocol outline for the siRNA transfection/infection experiments in mice.
group concentration/combination of siRNA’s (pmol) time of siRNA application Transfection reagent Infection
A sigB3 (187.5) 24 h before Ia lipofectamine Ab4
B sigB3 (187.5) 0.5 h before I lipofectamine Ab4
C siOri2 (187.5) 24 h before I lipofectamine Ab4
D siOri2 (187.5) 0.5 h before I lipofectamine Ab4
E sigB3/siOri2 (31.25/31.25) 24 h before I lipofectamine Ab4
F sigB3/siOri2 (31.25/31.25) 0.5 h before I lipofectamine Ab4
G sigB3/siOri2 (62.5/62.5) 24 h before I lipofectamine Ab4
H sigB3/siOri2 (62.5/62.5) 0.5 h before I lipofectamine Ab4
I siLuc (250) 24 h before I lipofectamine Ab4
J no siRNA 24 h before I lipofectamine Ab4
K siLuc (250) 12 h before I lipofectamine Ab4
L siLuc (250) 12 h before I PBS Ab4
M sigB3/siOri2 (62.5/62.5) 12 h before I lipofectamine Ab4
N sigB3/siOri2 (62.5/62.5) 6 h before I lipofectamine Ab4
O sigB3/siOri2 (62.5/62.5) 12 h before I PBS Ab4
P sigB3/siOri2 (62.5/62.5) 6 h before I PBS Ab4
Q sigB3/siOri2 (62.5/62.5) 1 h after I PBS Ab4
R sigB3/siOri2 (62.5/62.5) 6 h after I PBS Ab4
S sigB3/siOri2 (62.5/62.5) 12 h after I PBS Ab4
T sigB3/siOri2 (62.5/62.5) 24 h after I PBS Ab4
controlb no siRNA (PBS) 24 h before medium medium
control no siRNA (PBS) 12 h before medium Medium
aI: infection.
bcontrol: to evaluate weight loss due to anesthesia.
doi:10.1371/journal.pone.0004118.t001
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cantly reducing both weight loss (non-parametric statistical testing,
p,0.05, data not shown) and virus replication in the lungs
(Student’s t-test, p,0.05) (Figure 5B). Treatment with 62.5 pmol
sigB3/siOri2 6 h before EHV-1 infection did not significantly
reduce weight loss (data not shown); however, a significant
reduction of virus titers in the lungs 2 days p.i. was observed in
these mice (Student’s t-test, p,0.05) (Figure 5B).
Lastly, a third experiment was conducted to evaluate the effect
of siRNA treatment after infection. Mice (15 per group) were
infected with Ab4, followed by siRNA inoculation at 1, 6, 12 and
24 h after infection. The control group consisted of 15 untreated
infected mice as we could never observe any significant differences
between untreated and siLuc-treated mice in our previous
experiments. Viral loads in lungs were determined by viral
titrations and qPCR in five mice per group on day 3 p.i. The
amount of infectious virus, as determined by virus isolation, in
lungs of mice treated with siRNA’s at 1, 6 and 12 h infection was
significantly reduced (Student’s t-test, p,0.05) compared to
untreated infected animals (Figure 6A). No significant reduction
in virus titers was observed in animals treated with siRNA’s 24 h
post infection (p= 0.9). A reduction in viral genome copies in the
lungs of infected mice was observed at 1, 6 and 12 h p.i., but this
reduction only reached statistical significance in the group of mice
that were treated with siRNA’s 6 h post infection (Student’s t-test,
p,0.05; Figure 6B). These data show that treatment with siRNA’s
after infection is also efficient in reducing EHV-1 replication and
therefore indicate the potential of siRNA treatment during an
EHV-1 outbreak where several individuals might already have
been exposed to the virus.
Discussion
Over the course of the past few years, much progress has been
made in evaluating RNA interference as a novel potent therapy in
the fight against a number of virus infections of man and animals.
This progress has led to serious promise in terms of drug
development using small interfering (si)RNA technology and
intranasal application. For example, intranasal siRNA application
against respiratory syncytial virus (RSV) has recently entered
phase I clinical trials and it was shown that siRNA was safe and
well tolerated in healthy volunteers [33,34]. This area of research
is filling a therapeutical void and has provided evidence that
siRNA can possibly be developed into a treatment and/or
prevention option for respiratory viruses that are otherwise
difficult to control.
In the present study, we describe the use of siRNA against an
important respiratory pathogen in horses, the alphaherpesvirus
equine herpesvirus type 1 (EHV-1). EHV-1 is a major pathogen
which defies control measures as demonstrated by the increase in
severe, and often fatal, disease outbreaks which occur despite
Figure 4. siRNA’s are effective in reducing inflammatory responses in a murine model of EHV-1 infection when applied 0.5 h before
infection. (A). Development of mean body weights after infection. Balb/c mice (groups of 12) were transfected intranasally with sigB3 and
siOri2, alone or in combination, and mice were infected intranasally with 16105 PFU of Ab4 0.5 h later. Mice inoculated with 75 pmol siLuc were used
as positive controls and uninfected negative control mice were also included. Mean body weights were determined on the day of infection (day 0) up
to day 14 p.i. Mean body weights on the day of infection were set to 100%. Standard deviations (SD’s) ranged from 0.7 to 2.8%. The day of the
maximal SD’s for each group are indicated in brackets. The days where statistical significant differences (SS) were observed, as determined with non-
parametric Wicoxon-Whitney and Kruskal Wallis analyses, are also given between brackets. Histopathology. A total lung score was determined at
day 2 p.i. in three mice of each group and graded on a scale of 0+ (normal) to 5+ (severe), as described in Materials and Methods. Asterisks indicate
statistically significant differences (p,0.05) (B). Representative H&E images showing histological features in lungs of mice treated with the control
siLuc and mice treated with siRNA’s against EHV-1 genes. BH: bronchiolar hyperplasia, II: interstitial inflammation, BN: bronchiolar necrosis (C).
doi:10.1371/journal.pone.0004118.g004
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vaccination [7]. siRNA’s directed against highly conserved
essential EHV-1 genes were shown in an in vitro setting to
significantly reduce viral replication as measured by a significant
reduction in both number and size of plaques. The results
indicated that the selected siRNA’s interfered with EHV-1
infectivity and were capable of decreasing virus spread to
neighboring uninfected cells. The application of each siRNA was
readily effective, but when combined, a significant reduction in
infectivity was already observed when as little as 6.25 pmol of each
siRNA per 16106 cells in 2 mL of culture medium were used.
Interestingly, the effective concentration of our siRNA was far
below the in vitro siRNA concentrations described for other
respiratory pathogens like RSV, parainfluenza virus or SARS
coronavirus [35,36], indicating the potency of the selected siRNA’s
against EHV-1 genes tested in this study.
Using the well-established in vivo murine model of EHV-1
infection, we were also able to demonstrate that mice treated
intranasally with EHV-1-specific siRNA’s were protected against
clinical signs like weight loss. Importantly, the viral loads in the
lungs of treated mice were significantly lower as assessed by (i) viral
titration of lung tissues, (ii) quantitative real-time PCR and (iii)
histological evaluation of inclusion bodies. In addition, histological
evaluation of infected lung tissues of mice treated with control
siRNA’s directed against luciferase showed extensive perivascular
cuffing as well as interstitial inflammatory inflammation. In
contrast, significantly less inflammatory infiltrations and vascular
changes were observed in mice treated with siRNA’s that
specifically target EHV-1 genes. Another promising result of these
initial in vivo mice studies was that no significant difference could
be observed between the effectiveness of siRNA complexed with
the transfection reagent lipofectamine or with buffer (PBS). This
agrees with previous reports where strong activity of intranasally
administered naked siRNA was demonstrated in various animal
models [16,17,37].
One concern about using RNA interference against viruses is
escape from siRNA by mutation of the targeted sequences under
siRNA pressure. Mutational changes have been reported for RNA
viruses like human immunodeficiency or hepatitis C virus [38,39],
but no such escape mutation was found upon siRNA treatment
against other herpesviruses like HSV-2 [15]. Also in the present
study, sequence analysis of EHV-1 viral DNA isolated from lungs
of siRNA–treated infected mice did not show any mutations in the
targeted gB and Ori genes (data not shown), indicating that escape
mutation might not be as concerning for DNA viruses. In addition,
Figure 5. siRNA’s are effective in reducing viral replication when
applied before infection, even in the absence of a transfection
reagent. In a first experiment, Balb/c mice (groups of 12) were
transfected intranasally with sigB3 and siOri2, alone or in combination,
and mice were infected intranasally with 16105 PFU of Ab4 0.5 h later
(A). In a second experiment, Balb/c mice (groups of 12) were inoculated
intranasally with 62.5 pmol sigB3/siOri2, complexed with lipofectamine
(closed symbols) or in PBS (open symbols) 6 or 12 h before infection with
16105 PFU of Ab4 (B). Mice transfected with 75 pmol siLuc were used as
positive controls and viral titers were determined in three mice of each
group on day 2 p.i. Titers in lungs and standard deviations are shown.
Asterisks indicate statistically significant differences (p,0.05) between
mice transfected with sigB3 and siOri2, alone or in combination, andmice
transfected with the control siRNA siLuc.
doi:10.1371/journal.pone.0004118.g005
Figure 6. siRNA’s are effective in reducing viral replication
when applied after infection. Balb/c mice (groups of 15) were
infected intranasally with 16105 PFU of Ab4. At 1, 6, 12 or 24 h post-
infection, mice were inoculated intranasally with 62.5 pmol sigB3/siOri2,
in PBS. (A). Viral titers were determined in lungs of five mice per group
on day 3 p.i. by co-cultivation. Titers in lungs and standard deviations
are shown. (B). Viral loads in lung tissues were also measured by qPCR
and are plotted as EHV-1 genome (IR6 gene) copies per million mouse
iNOS gene copies. Asterisks indicate statistically significant differences
(p,0.05; Student’s t-test) between untreated mice and mice inoculated
with 62.5 pmol sigB3/siOri2.
doi:10.1371/journal.pone.0004118.g006
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we used a combination of siRNA’s against two different essential
genes, hereby further reducing the likelihood of escape mutations.
Another concern raised is the question of whether the effect
observed upon siRNA addition is caused by the induction of an
immune response, e.g. IFN-c responses, upon delivery of the
nucleic acids or by a specific action of the chosen siRNA. We did
not focus extensively on the potential induction of an innate
immune response following application of siRNA against EHV-1.
However, it has been previously reported that interferon responses
mostly occur in vitro and depend more on the transfection reagent
than the actual siRNA [40,41]. In addition, several in vivo studies,
including one assessing intranasally applied siRNA against RSV,
were unable to reveal any siRNA-induced interferon responses
[17,42]. These data led us to assume that the induction of an
innate immune response upon intranasal administration of siRNA
against EHV-1 genes would also be unlikely. Furthermore, the
control siRNA’s siLuc and siGFP both failed to have any silencing
effect on EHV-1, lending additional support for the notion that the
observed effects using gB- and Ori-specific siRNA’s are indeed
specific.
A major bottleneck in the development of siRNA therapy is
optimization of the potency and half-life of siRNA’s in order to be
efficacious in a realistic clinical setting. What modifications are
optimal will likely depend on the clinical indication and the
strategy used to deliver the siRNA. For example, incorporation
into complexes and particles has been shown to offer quite variable
protection of siRNA from exposure to endogenous nucleases [43].
Therefore, unmodified siRNA’s may be particularly useful in
situations in which long-term silencing is not required, such as
treating acute viral infections in humans and animals. Notably,
many of the in vivo studies that have shown disease protection used
unmodified siRNA’s that were not optimized for half-life [33,34],
similar to the data in our manuscript. An example of great interest
and potential is the development of an siRNA drug candidate
against RSV, where clinical trails demonstrated that low dosages
of inhaled uncomplexed siRNA are a potent and easy way to
administer antiviral therapeutics against respiratory viral diseases
in humans (www.alnylam.com).
In the present study, we were also able to demonstrate the
potential use of siRNA as a therapeutic alternative for the
treatment of the animal respiratory viral disease caused by EHV-1
in a murine model. Besides showing the effectiveness of siRNA
against EHV-1 when applied before infection, we demonstrated
that siRNA application to mice after challenge infection was
effective in reducing clinical symptoms and virus replication in the
lungs of treated animals. This might be of particular importance in
the case of EHV-1 outbreak situations where in contact or
previously exposed horses are treated. Based on our results, it is
conceivable that if siRNA’s are applied during an outbreak, not
only the severity of clinical signs of affected horses but also the
number of affected horses and the magnitude of nasal shedding
could be reduced, resulting in an overall reduction of the viral load
in the population and improved control of the outbreak.
The effectiveness of the intranasal siRNA therapy needs to be
evaluated in the target species before any firm conclusions can be
drawn and experiments are under way to address this question. An
important fact is the complex pathogenesis of EHV-1 in the horse
compared to the murine model. Intranasal infection of mice
usually remains restricted to the respiratory tissues, while in the
horse EHV-1 targets the respiratory tract, the pregnant uterus and
the central nervous system. However, by specifically targeting the
nasal mucosa, the site of initial EHV-1 invasion and replication,
this model of attenuation of disease in mice may be predictive for
the horse.
The set of in vitro and in vivo experiments in the present study
were designed to show that siRNA therapy targeting viral genes
important for cell entry and replication is effective in decreasing
severity of EHV-1 infection and disease. Not only was it possible to
decrease the amount of infectious viral particles produced upon
infection, it was also possible to decrease clinical signs. The
findings have important implications in terms of treating and
preventing outbreaks of EHV-1, as neither effective therapeutic
nor prophylactic measures for this important disease are currently
available. Taken together, the potential use of RNA interference in
the control of EHV-1 infections by intranasal application of
siRNA was demonstrated and could prove an effective means to
control EHV-1 infections as metaphylactic and/or therapeutic
measures in outbreak situations.
Materials and Methods
Cells, Viruses and siRNA’s
Rabbit kidney (RK13) cells were maintained in minimum
essential medium (MEM, Mediatech Inc.) supplemented with 10%
fetal bovine serum (FBS), 100 U/mL penicillin and 0.1 mg/mL
streptomycin (Mediatech Inc.), at 37uC under 5% CO2 atmo-
sphere. Wild type EHV-1 strain Ab4 and the eGFP-expressing
rAb4Dgp2 were propagated in RK13 cells [44]. The small
interfering RNAs (siRNA’s) against ORF33 (encoding gB) and
ORF53 (encoding the helicase, Ori) were chemically synthesized
(Ambion) based on the sequence of Ab4 (Genbank Sequence
#AY665713) (Table 2).
siRNA treatment and virus infection
Six-well plates of RK13 cells were treated with different
concentrations of siRNA, ranging from 0 up to 75 pmol. The
siRNA’s were complexed with lipofectamine as per the manufac-
turers instructions (Invitrogen) and added to the cells in a total
volume of 500 mL/well. After 2 hours of incubation at 37uC,
1.5 mL/well of growth media were added and incubated for 14 h.
After washing, cells were inoculated with 100 plaque forming units
(PFU)/well of eGFP-expressing rAb4Dgp2. One hour post
infection (p.i.), medium was removed and infected cells were
Table 2. siRNA sequences.
name gene target (protein) siRNA sequence (59R39)a
sigB1 ORF33 (gB) GGAUGGAGACUUUUACACCtt
GGUGUAAAAGUCUCCAUCCtc
sigB2 ORF33 (gB) GGAGAACGAGAUUUUCACGtt
CGUGAAAAUCUCGUUCUCCtc
sigB3 ORF33 (gB) CGGAAAUCGAGGUUAUCAGtt
CUGAUAACCUCGAUUUCCGtg
siOri1 ORF53 (helicase) CGAUAACCUCCUCAACAAUtt
AUUGUUGAGGAGGUUAUCGtc
siOri2 ORF53 (helicase) CGAUGGUUCACCUCAACAAtt
UUGUUGAGGUGAACCAUCGta
siOri3 ORF53 (helicase) CGGAGGUUUUUGAAAACGAtt
UCGUUUUCAAAAACCUCCGtc
siLuc Firefly Luciferase Accession No: U47296
siGFP eGFP Accession No: U55761
abold indicates siRNA’s that showed significant reduction of EHV-1 replication.
doi:10.1371/journal.pone.0004118.t002
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overlaid with fresh medium. Supernatants were collected at 24 h
p.i. and cells were fixed with 10% formalin in phosphate buffered
saline (PBS). To determine plaque sizes, at least 50 plaques per
well were photographed and the average plaque areas were
determined using the Image J software (http://rsb.info.nih.gov/ij).
To determine extracellular viral titers, a standard plaque assay was
used, essentially as described before [30]. Briefly, 10-fold dilutions
of supernatants were plated on RK13 cells and 3 days p.i. cells
were fixed with 10% formalin in PBS, stained with 0.3% crystal
violet and plaques were counted.
To evaluate the effectiveness of siRNA administration in
relation to time of infection, siRNA’s were added 12, 6 and 2 h
prior to EHV-1 infection; simultaneously with EHV-1 infection;
and 1 h after EHV-1 infection.
Western blotting
Western blot analyses were performed exactly as described
previously [30]. To detect gB, mAb 3F6 was used at a 1:500
dilution (kindly provided by Dr. G.P. Allen, University of
Kentucky) [45]. Anti b-actin (Sigma), at a 1:5000 dilution, was
used as a control antibody. Anti-mouse IgG peroxidase conjugate
was obtained from ImmunoResearch Laboratories and used at a
dilution of 1:5000.
RNA extraction and real-time quantitative RT-PCR (qRT-
PCR)
Six-well plates of RK13 cells were transfected with siRNA and
infected 14 h later with wild-type Ab4 as described above. At 12
and 24 h p.i. cells were collected and following a freeze-thaw cycle,
RNA was extracted using RNA STAT-60 (Tel-Test Inc. Friends-
wood, TX) essentially as described before [46]. Briefly, dried RNA
pellets were dissolved in 100 ml RNase-free water and all RNA
samples were DNase-treated with the Turbo DNA-free kit,
according to the manufacturer’s instructions (Ambion). cDNA
was synthesized using the Thermoscript RT-PCR system (Invitro-
gen) according to the manufacturer’s instructions using random
hexamers with Thermoscript reverse transcriptase. qPCR was
performed using the 7500-FAST real-time PCR system (Applied
Biosystems) with reaction mixtures containing TaqMan Fast
Universal PCR Master Mix, 900 nM primers, 250 nM probe
and 5 mL cDNA, in a 20 ml total reaction volume. Parameters
included 95 C for 20 sec to activate Taq polymerase, followed by
40 cycles of 95 C63 sec and 60 C630 sec. The primers and
probes used are listed in Table 3 and the comparative CT method
for relative quantitation (22DDCT) was used with rabbit b-actin as
the endogenous housekeeping gene [6,44].
Animal experiments
All animal experiments were performed in accordance with the
U.S. Animal Welfare Act, under the supervision of Cornell
University’s Animal Care and Use Committee, and were
conducted as previously described with some modifications [30].
Three-to-four week-old female BALB/c mice (12 mice per group)
were inoculated with varying concentrations and combinations of
siRNA’s and infected with 16105 PFU of the EHV-1 strain Ab4,
as described in Table 1. Suspensions of siRNA’s, with or without
the transfection reagent lipofectamine in 20 mL OptiMEM or PBS
respectively, and Ab4 in 20 mL MEM were administered
intranasally (Table 1). Individual weights of mice were determined
daily on the day of infection (day 0) up to day 14 p.i. Three mice
from each group were euthanized to collect lungs on days 2 and 4
p.i. The left lobes were homogenized to determine viral titers on
RK13 cells by standard plaque assays. The right lobes were fixed
in 10% formaldehyde solution and processed for histopathological
analysis. H&E-stained lung sections of three mice per group were
scored in a double-blinded manner under the light microscope to
determine the degree of inflammation, bronchiolar changes
(hyperplasia and/or necrosis) and the presence of inclusion bodies.
A value of 0 (normal), 1 (minimal), 2 (mild), 3 (moderate), 4
(marked) or 5 (severe) was assigned for each histological parameter
and the scores per group were computed as the total lung score per
group. In another set of experiments, five mice per group were
euthanized on day 3 p.i. to collect lungs for viral titrations and
additional determination of the viral genome load in these tissues
Table 3. Primers and Probes used in the study.
Real time PCR
Gene Primers (59R39) a MGB probe
EHV-1 IR6 F: GCGAAGTACCCCTCGTTCATCT TCGCGACACCGCCT
R: ATGCTCGGGCGCTCCTACT
EHV-1 gB F: CGCTGAGGATGGAGACTTTTACA CCACCGCCTACCGGATCCACC
R: GGTGGTTCGATGCGTACG
EHV-1 Ori F: TGGTAACGGTGGGCCTTAGT TTGATACGGCTCATT TCCACAGC
R: GGGCTTGACGTAGGCAAACA
rabbit b-actin F: CGAGATCGTGCGGGACAT AAGGAGAAGCTGTGCTACGTGGCGCT
R: GCCATCTCCTGCTCGAAGTC
Sequencing
Gene Primers (59R39) a
EHV-1 gB F: TTTGGAAGCTGTGTTGTTAGAG
R: TAATCACTGCGGTATTGTCCA
EHV-1 Ori F: CACTTGCACCAGCCACGTTC
R: CATGGGGGTAAAGATGGGCT
aF: Forward primer, R: Reverse primer.
doi:10.1371/journal.pone.0004118.t003
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by qPCR, which was performed exactly as previously described
[44].
Statistical analysis
Student’s t-test for paired data was used to test for differences.
Data given are the means and bars show standard deviations.
Body weights were compared using non-parametric Wilcoxon-
Whitney and Kruskal Wallis tests. All statistical calculations were
performed with SAS vs. 9.1. (SAS Corporation, Cary, NC).
Acknowledgments
The authors are grateful to Cassandra Shores and Laura Goodman for
their invaluable help with the RT-PCR. We thank Kerstin Osterrieder for
statistical analyses; we are indebted to the late George P. Allen for
providing monoclonal antibodies, and thank Hillary Wentworth for her
assistance with the animal experiments.
Author Contributions
Conceived and designed the experiments: STP NO GRVdW. Performed
the experiments: AJF STP GAP KWJ AD MMB GRVdW. Analyzed the
data: KWJ ELB. Wrote the paper: AJF NO GRVdW.
References
1. Pellett PaRB (2007) Herpesviridae. 5th edition, Fields Virology. Philadelphia:
Lippincott, Wilkinson and Wilkins. pp 2479–2499.
2. Allen GP, Bryans JT (1986) Molecular epizootiology, pathogenesis, and
prophylaxis of equine herpesvirus-1 infections. Prog Vet Microbiol Immunol
2: 78–144.
3. Gibson JS, Slater JD, Awan AR, Field HJ (1992) Pathogenesis of equine
herpesvirus-1 in specific pathogen-free foals: primary and secondary infections
and reactivation. Arch Virol 123: 351–66.
4. USDA-APHIS. Equine herpesvirus myeloencephalopathy: A potential emerging
disease. 2007. Internet Communication.
5. Kydd JH, Townsend HG, Hannant D (2006) The equine immune response to
equine herpesvirus-1: the virus and its vaccines. Vet Immunol Immunopathol
111: 15–30.
6. Goodman LB, Wagner B, Flaminio MJ, Sussman KH, Metzger SM, et al. (2006)
Comparison of the efficacy of inactivated combination and modified-live virus
vaccines against challenge infection with neuropathogenic equine herpesvirus
type 1 (EHV-1). Vaccine 24: 3636–45.
7. Henninger RW, Reed SM, Saville WJ, Allen GP, Hass GF, et al. (2007)
Outbreak of neurologic disease caused by equine herpesvirus-1 at a university
equestrian center. J Vet Intern Med 21: 157–65.
8. Garre B, Shebany K, Gryspeerdt A, Baert K, van der Meulen K, et al. (2007)
Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after
oral administration of acyclovir and its prodrug valacyclovir in healthy adult
horses. Antimicrob Agents Chemother 51: 4308–14.
9. Garre B, van der Meulen K, Nugent J, Neyts J, Croubels S, et al. (2007) In vitro
susceptibility of six isolates of equine herpesvirus 1 to acyclovir, ganciclovir,
cidofovir, adefovir, PMEDAP and foscarnet. Vet Microbiol 2007 122: 43–51.
10. Garre B, Gryspeerdt A, Croubels S, De Backer P, Nauwynck H (2008)
Evaluation of orally adminstered valacyclovir in experimentally EHV1-infected
ponies. Vet.Microbiol; doi:10.1016/j.tvjl.2008.03.027.
11. Dykxhoorn DM, Lieberman J (2006) Knocking down disease with siRNAs. Cell
126: 231–5.
12. Dykxhoorn DM, Lieberman J (2006) Silencing viral infection. PLoS Med 3:
e242.
13. Zhang J, Wu YO, Xiao L, Li K, Chen LL, et al. (2007) Therapeutic potential of
RNA interference against cellular targets of HIV infection. Mol Biotechnol 37:
225–36.
14. Scherer L, Rossi JJ, Weinberg MS (2007) Progress and prospects: RNA-based
therapies for treatment of HIV infection. Gene Ther 14: 1057–64.
15. Palliser D, Chowdhury D, Wang QY, Lee SJ, Bronson RT, et al. (2006) An
siRNA-based microbicide protects mice from lethal herpes simplex virus 2
infection. Nature 439: 89–94.
16. Li BJ, Tang Q, Cheng D, Qin C, Xie FY, et al. (2005) Using siRNA in
prophylactic and therapeutic regimens against SARS coronavirus in Rhesus
macaque. Nat Med 11: 944–51.
17. Bitko V, Musiyenko A, Shulyayeva O, Barik S (2005) Inhibition of respiratory
viruses by nasally administered siRNA. Nat Med 11: 50–5.
18. Neubauer A, Braun B, Brandmuller C, Kaaden OR, Osterrieder N (1997)
Analysis of the contributions of the equine herpesvirus 1 glycoprotein gB
homolog to virus entry and direct cell-to-cell spread. Virology 227: 281–94.
19. Martin DW, Deb S (1994) Cloning and expression of an equine herpesvirus 1
origin-binding protein. J Virol 68: 3674–81.
20. Martin DW, Munoz RM, Oliver D, Subler MA, Deb S (1994) Analysis of the
DNA-binding domain of the HSV-1 origin-binding protein. Virology 198:
71–80.
21. Hutvagner G, Simard MJ, Mello CC, Zamore PD (2004) Sequence-specific
inhibition of small RNA function. PLoS Biol 2: e98.
22. Awan AR, Chong YC, Field HJ (1990) The pathogenesis of equine herpesvirus
type 1 in the mouse: a new model for studying host responses to the infection.
J Gen Virol 71: 1131–40.
23. van Woensel PA, Goovaerts D, Markx D, Visser N (1995) A mouse model for
testing the pathogenicity of equine herpes virus-1 strains. J Virol Methods 54:
39–49.
24. Colle CF III, Tarbet EB, Grafton WD, Jennings SR, O’Callaghan DJ (1996)
Equine herpesvirus-1 strain KyA, a candidate vaccine strain, reduces viral titers
in mice challenged with a pathogenic strain, RacL. Virus Res 43: 111–24.
25. Ruitenberg KM, Walker C, Wellington JE, Love DN, Whalley JM (1999)
Potential of DNA-mediated vaccination for equine herpesvirus 1. Vet Microbiol
68: 35–48.
26. Ruitenberg KM, Walker C, Wellington JE, Love DN, Whalley JM (1999) DNA-
mediated immunization with glycoprotein D of equine herpesvirus 1 (EHV-1) in
a murine model of EHV-1 respiratory infection. Vaccine 17: 237–44.
27. Frampton AR Jr, Smith PM, Zhang Y, Matsumura T, Osterrieder N, et al.
(2002) Contribution of gene products encoded within the unique short segment
of equine herpesvirus 1 to virulence in a murine model. Virus Res 90: 287–301.
28. Galosi CM, Barbeito CG, Vila Roza MV, Cid dlP V, Ayala MA, et al. (2004)
Argentine strain of equine herpesvirus 1 isolated from an aborted foetus shows
low virulence in mouse respiratory and abortion models. Vet Microbiol 103:
1–12.
29. Tsujimura K, Yamanaka T, Kondo T, Fukushi H, Matsumura T (2006)
Pathogenicity and immunogenicity of equine herpesvirus type 1 mutants
defective in either gI or gE gene in murine and hamster models. J Vet Med Sci
68: 1029–38.
30. von Einem J, Smith PM, Van de Walle GR, O’Callaghan DJ, Osterrieder N
(2007) In vitro and in vivo characterization of equine herpesvirus type 1 (EHV-1)
mutants devoid of the viral chemokine-binding glycoprotein G (gG). Virology
362: 151–62.
31. Van de Walle GR, Sakamoto K, Osterrieder N (2008) CCL3 and viral
chemokine-binding protein gG modulate pulmonary inflammation and virus
replication during equine herpesvirus type 1 (EHV-1) infection. J Virol 82:
1714–1722.
32. Van de Walle GR, May ML, Sukhumavasi W, von Einem J, Osterrieder N
(2007) Herpesvirus chemokine-binding glycoprotein G (gG) efficiently inhibits
neutrophil chemotaxis in vitro and in vivo. J Immunol 179: 4161–9.
33. Barik S, Bitko V (2006) Prospects of RNA interference therapy in respiratory
viral diseases: update 2006. Expert Opin Biol Ther 6: 1151–60.
34. Bitko V, Barik S (2007) Intranasal antisense therapy: preclinical models with a
clinical future? Curr Opin Mol Ther 9: 119–25.
35. Bitko V, Barik S (2001) Phenotypic silencing of cytoplasmic genes using
sequence-specific double-stranded short interfering RNA and its application in
the reverse genetics of wild type negative-strand RNA viruses. BMCMicrobiol 1:
34.
36. Zheng BJ, Guan Y, Tang Q, Du C, Xie FY, et al. (2004) Prophylactic and
therapeutic effects of small interfering RNA targeting SARS-coronavirus. Antivir
Ther 9: 365–74.
37. Massaro D, Massaro GD, Clerch LB (2004) Noninvasive delivery of small
inhibitory RNA and other reagents to pulmonary alveoli in mice. Am J Physiol
Lung Cell Mol Physiol 287: 1066–1070.
38. Boden D, Pusch O, Lee F, Tucker L, Ramratnam B (2003) Human
immunodeficiency virus type 1 escape from RNA interference. J Virol 77:
11531–5.
39. Wilson JA, Richardson CD (2005) Hepatitis C virus replicons escape RNA
interference induced by a short interfering RNA directed against the NS5b
coding region. J Virol 79: 7050–8.
40. Sledz CA, Holko M, de Veer MJ, Silverman RH, Williams BR (2003) Activation
of the interferon system by short-interfering RNAs. Nat Cell Biol 5: 834–9.
41. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, et al. (2005) Sequence-
dependent stimulation of the mammalian innate immune response by synthetic
siRNA. Nat Biotechnol 23: 457–62.
42. Heidel JD, Hu S, Liu XF, Triche TJ, Davis ME (2004) Lack of interferon
response in animals to naked siRNAs. Nat Biotechnol 22: 1579–82.
43. Dallas A, Vlassov AV (2006) RNAi: a novel antisense technology and its
therapeutic potential. Med Sci Monit 12: 67–74.
44. Goodman LB, Loregian A, Perkins GA, Nugent J, Buckles EL, et al. (2007) A
point mutation in a herpesvirus polymerase determines neuropathogenicity.
PLoS Pathog 3: e160.
45. Allen GP, Yeargan MR (1987) Use of lambda gt11 and monoclonal antibodies
to map the genes for the six major glycoproteins of equine herpesvirus 1. J Virol
61: 2454–61.
46. Jarosinski KW, Schat KA (2007) Multiple alternative splicing to exons II and III
of viral interleukin-8 (vIL-8) in the Marek’s disease virus genome: the importance
of vIL-8 exon I. Virus Genes 34: 9–22.
EHV-1 Treatment Using siRNA
PLoS ONE | www.plosone.org 10 January 2009 | Volume 4 | Issue 1 | e4118
